Boothbay Fund Management, LLC Iveric Bio, Inc. Transaction History

Boothbay Fund Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $1.59 Million - $2.41 Million	60,713 Added 150.7%	101,000 $3.97 Million
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $3.13 Million - $4.12 Million	-167,690 Reduced 80.63%	40,287 $980,000
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $481,133 - $668,396	27,908 Added 15.5%	207,977 $4.45 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $1.69 Million - $3.35 Million	180,069 New	180,069 $3.23 Million
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $300,028 - $407,413	-21,694 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $153,376 - $379,645	21,694 New	21,694 $352,000
Q1 2021 May 17, 2021	SELL	$5.08 - $6.89 $80,985 - $109,840	-15,942 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$5.65 - $7.66 $19,407 - $26,312	3,435 Added 27.46%	15,942 $110,000
Q3 2020 Nov 16, 2020	BUY	$4.01 - $6.29 $50,153 - $78,669	12,507 New	12,507 $71,000
Q4 2019 Feb 14, 2020	SELL	$0.93 - $8.58 $86,985 - $802,513	-93,533 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$1.21 - $1.48 $113,174 - $138,428	93,533 New	93,533 $122,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.